Arcus Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arcus Biosciences, Inc. - overview
Established
2015
Location
Hayward, CA-California, US
Primary Industry
Biotechnology
About
Founded in 2015 and based in California, US, Arcus Biosciences, Inc. is a biotechnology company that develops immunotherapies for the treatment of cancer. In January 2024, Gilead Sciences, Inc. acquired Arcus Biosciences, Inc.
for USD 320 million in common stock at USD 21. 00 per share. The firm as of July 2024, has offices in Hayward and Brisbane, California, and is led by its CEO, Terry Rosen. Arcus Biosciences has a robust pipeline of clinical candidates targeting various biological pathways critical to cancer progression.
These include Anti-TIGIT (domvanalimab), Adenosine Axis (etrumadenant, quemliclustat), Anti-PD-1 (zimberelimab), HIF-2⍺ Inhibitor (casdatifan), Anti-CD39 (AB598), and AXL Inhibitor (AB801). These candidates are designed to address high unmet medical needs across multiple cancer types, such as lung, gastrointestinal, kidney, pancreatic, and colorectal cancers. The company's development approach is moving from program initiation to investigational new drug (IND) filing in record time, and progressing rapidly through clinical phases. The January 2024 acquisition will allow Arcus to concentrate on developing several pipeline assets, including both Gilead-optioned and non-optioned initiatives, while also assisting Gilead Sciences, Inc.
in expediting the domvanalimab program.
Current Investors
The Column Group, Celgene, Foresite Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.arcusbio.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Arcus Biosciences, Inc. - timeline of key events
Arcus Biosciences, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Jul 31, 2025 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 8,353,000 | 15,000,000 | 77,517,000 | 382,882,000 | 112,000,000 | 117,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | 79.6% | 416.8% | 393.9% | (70.7%) | 4.5% | - | - | - |
| EBITDA (USD) | (52,947,000) | (87,769,000) | (120,090,000) | 62,863,000 | (274,000,000) | (351,000,000) | - | - | - |
| Operating Income (USD) | (54,859,000) | (88,709,000) | (124,235,000) | 54,248,000 | (280,000,000) | (340,000,000) | - | - | - |
| Operating Margin | (656.8%) | (591.4%) | (160.3%) | 14.2% | (250.0%) | (290.6%) | - | - | - |
| % EBITDA Margin | (633.9%) | (585.1%) | (154.9%) | 16.4% | (244.6%) | (300.0%) | - | - | - |
| NET Income (USD) | (49,594,000) | (84,710,000) | (122,858,000) | 52,830,000 | (267,000,000) | (307,000,000) | - | - | - |
| % Net Margin | (593.7%) | (564.7%) | (158.5%) | 13.8% | (238.4%) | (262.4%) | - | - | - |
Arcus Biosciences, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Venture Debt | Completed | Arcus Biosciences, Inc. | - | ||||||||
| Trade Sale | Completed | Arcus Biosciences, Inc. | - | ||||||||
| IPO | Completed | Arcus Biosciences, Inc. | - | ||||||||
| Series C | Completed | Arcus Biosciences, Inc. | - | ||||||||
| Series B | Completed | Arcus Biosciences, Inc. | - |
Displaying 1 - 5 of 6
Arcus Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.